Messoud Ashina

The burden of migraine: from individuals to society 2:43
The burden of migraine: from individuals to society
Messoud Ashina • 23 Jun 2022
Anti-CGRP monoclonal antibodies for difficult to treat migraines: DELIVER trial 1:47
Anti-CGRP monoclonal antibodies for difficult to treat migraines: DELIVER trial
Messoud Ashina • 23 Jun 2022
PACAP as a future target for anti-migraine medication 3:04
PACAP as a future target for anti-migraine medication
Messoud Ashina • 23 Jun 2022
Real-world studies show effectiveness of anti-CGRP mAbs in difficult to treat patients with migraine 3:19
Real-world studies show effectiveness of anti-CGRP mAbs in difficult to treat patients with migraine
Messoud Ashina • 23 Jun 2022
Latest guidelines on anti-CGRP antibodies: first-line and long-term use 2:24
Latest guidelines on anti-CGRP antibodies: first-line and long-term use
Messoud Ashina • 23 Jun 2022
BKCa channels: potential novel anti-migraine target 4:14
BKCa channels: potential novel anti-migraine target
Messoud Ashina • 29 May 2020
PROMISE-1: eptinezumab in episodic migraine 2:44
PROMISE-1: eptinezumab in episodic migraine
Messoud Ashina • 29 May 2020
The evolving migraine prevention landscape: EAN 2020 highlights 3:29
The evolving migraine prevention landscape: EAN 2020 highlights
Messoud Ashina • 29 May 2020
PEARL study: fremanezumab for chronic or episodic migraine in the real world 3:16
PEARL study: fremanezumab for chronic or episodic migraine in the real world
Messoud Ashina • 29 May 2020
The content of VJNeurology is intended for healthcare professionals